Treatment of HIV/HCV Coinfection With Peg-IFN and Ribavirin in Patients Receiving ART Monotherapy With Lopinavir/r (PEKARI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00866021|
Recruitment Status : Completed
First Posted : March 20, 2009
Last Update Posted : March 22, 2013
|Condition or disease||Intervention/treatment||Phase|
|HIV/HCV Co-infection HIV Infections||Drug: Lopinavir/ritonavir Drug: Lopinavir/ritonavir with two nucleoside analogs||Phase 4|
Viral hepatitis, mainly when caused by the hepatitis C virus (HCV), is highly significant in the setting of infection by the human immunodeficiency virus (HIV) because high activity antiretroviral therapy (HAART) has a very favorable impact upon morbidity and mortality of this disease. HAART has achieved disease control, significantly increasing survival and improving the quality of life of subjects with HIV infection.
Spain has one of the highest prevalences of HIV-HCV co-infection because both HCV and HIV infection are strongly associated to being or having been an intravenous drug user (IDU); thus, from 61% to 69% of these subjects infected by HIV in Spain are also infected by HCV.
From 1998, standard treatment for chronic C hepatitis consists of the combination of interferon alpha and ribavirin, based on an increased efficacy versus interferon monotherapy; however, development of pegylated interferon, with a more convenient bioavailability as compared to conventional interferon alpha, has allowed for developing even more effective combined therapies and the possibility of improving response prediction based on changes in viremia within the first few weeks of treatment. However, treatment of HCV infection usually involves severe side effects, which often lead to treatment discontinuation or to the need for adjusting drug dosage, in which case treatment efficacy may decrease.
HCV+ subjects who, because of HIV co-infection, should also receive HAART, may have an increased number or increased severity of adverse reactions due to interactions occurring with drug co-administration.
Lopinavir/ritonavir (LPV/r) is a potent HIV protease inhibitor and is characterized by a very high pharmacological and genetic barrier.
Different studies (subject cohorts, uncontrolled studies) during the past years have appeared in the literature showing the efficacy of LPV/r or controlling viral replication.
Most studies were conducted with the soft gel capsule formulation of LPV/r. In this study, the new formulation of LPV/r (Kaletra) as tablets approved by the FDA and EMEA (Spain authorization 30th Oct 2006) will be used. This new formulation will provide additional benefits to this strategy that has only been studied to date with soft gel capsules.
Based on the foregoing and on the additional cost savings involved in this strategy, we think that LPV/r, as single antiretroviral agent concomitantly administered with treatment for hepatitis C virus infection may provide significant benefits because it would prevent interactions between NRTIs and ribavirin, thus being potentially able to decrease the adverse events derived from mitochondrial toxicity and minimizing the possibility of anemia. In addition, replacement of NNRTIs by LPV/r may significantly decrease CNS involvement that may be enhanced by co-administration of efavirenz and peg-interferon, or minimize the risk of hepatotoxicity caused by nevirapine.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||68 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multicenter, Randomized, Open Label, Pilot Study to Assess the Possibility of Concomitant Treatment of HCV/HIV co Infection With Peg-interferon + Ribavirin, and Lopinavir/r as a Single Antiretroviral Agent.|
|Study Start Date :||February 2008|
|Actual Primary Completion Date :||June 2012|
|Actual Study Completion Date :||October 2012|
Lopinavir/ritonavir (LPV/r) as single antiretroviral administered concomitantly with peg-interferon and ribavirin
Other Name: Kaletra
Active Comparator: 2
Lopinavir/ritonavir (LPV/r) with 2 NRTIs, administered concomitantly with peg-interferon and ribavirin
Drug: Lopinavir/ritonavir with two nucleoside analogs
LPV/r plus 2NRTIs + PEG-INF + RBV
- Assess efficacy of concomitant treatment with lopinavir/r monotherapy and PEG-INF plus RBV for the control of both HIV and HCV infection respectively after 12 months of active treatment for HCV [ Time Frame: 80 weeks ]
- Tolerability and safety of concomitant treatment with LPV/r, PEG-INF and RBV [ Time Frame: 80 weeks ]
- CD4 [ Time Frame: 80 weeks ]
- Efficacy [ Time Frame: 80 weeks ]
- Adherence [ Time Frame: 80 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00866021
|Hospital Germans Trias i Pujol|
|Badalona, Barcelona, Spain, 08910|
|San Sebastian, Guipuzcoa, Spain|
|Hospital General Sta. Mª del Rosell|
|Cartagena, Murcia, Spain, 30203|
|Hospital General de Castellón|
|Castellón, Spain, 12004|
|Hospital Gregorio Marañón|
|Madrid, Spain, 28007|
|Hospital Ramón y Cajal|
|Madrid, Spain, 28034|
|Hospital la Paz|
|Madrid, Spain, 28046|
|Hospital La Princesa|
|Hospital La Fe|
|Valencia, Spain, 46009|
|Hospital General Universitario de Valencia|
|Valencia, Spain, 46014|
|Study Chair:||Enrique Ortega||Hospital General Universitario de Valencia|